Chemioterapia w guzach neuroendokrynnych układu pokarmowego (GEP-NEN) Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
gru 31, 2012
Słowa kluczowe:
nowotwory neuroendokrynne przewodu pokarmowego (GEP-NEN), chemioterapia
##plugins.themes.bootstrap3.article.main##
Abstrakt
Nowotwory neuroendokrynne układu pokarmowego w chwili rozpoznania choroby są w stadium rozsianym u ok. 2/3 chorych. Chemioterapia z użyciem schematu cisplatyna + etopozyd pozostaje standardem w przypadku zaawansowanych postaci niskozróżnicowanych raków neuroendokrynnych (NEC G3 wg klasyfikacji WHO z 2010 r.). W przypadku dobrze zróżnicowanych nowotworów neuroendokrynnych trzustki streptozotocyna, doksorubicyna i/lub 5-Fu są uważane za chemioterapię standardową, mimo że nie ma randomizowanych badań porównujących ją z innymi terapiami. Międzynarodowe wytyczne nie rekomendują stosowania chemioterapii w rozsianych nowotworach neuroendokrynnych pochodzących ze środkowego odcinka prajelita (midgut). Chorzy ci powinni być kwalifikowani do innego typu leczenia.
Pobrania
Dane pobrania nie są jeszcze dostepne
##plugins.themes.bootstrap3.article.details##
Jak cytować
1.
Kolasińska-Ćwikła A. Chemioterapia w guzach neuroendokrynnych układu pokarmowego (GEP-NEN). OncoReview [Internet]. 31 grudzień 2012 [cytowane 23 listopad 2024];2(4(8):255-61. Dostępne na: https://journalsmededu.pl/index.php/OncoReview/article/view/319
Numer
Dział
Artykuły
Utwór dostępny jest na licencji Creative Commons Uznanie autorstwa – Użycie niekomercyjne 4.0 Międzynarodowe.
Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
Bibliografia
1. Rindi B., Bordi C.: Etiology, molecular pathogenesis and genetics. Best Pract. Res. Clin. Gastroenterology 2005; 19: 519-534.
2. Gaur P., Sceusi E.L., Samuel S. et al.: Identification of cancer stem cells in human gastrointestinal carcinoid and neuroendocrine tumors. Gastroenterology 2011; 141: 1728-1737.
3. Modlin I.M., Oberg K., Chung D.C. et al.: Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol. 2008; 9: 61-72.
4. Kos-Kudła B.: Polskie zalecenia diagnostyczno-lecznicze w guzach neuroendokrynnych układu pokarmowego (GEP NET). Nowotwory J. of Oncology 2006; 56: 584-589.
5. Oberg K.: Pancreatic endocrine tumors. Semin. Oncol. 2010; 37: 594-618.
6. Kulke M.H., Siu L.L., Tepper J.E. et al.: Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting. J. Clin. Oncol. 2011; 29: 934-943.
7. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology, Neuroendocrine Tumors Version 1.2011. Online: http://www.nccn.org.
8. Bosman F., Carneiro F., Hruban R. et al.: WHO classification of tumors of digestive system. Lyon, IARC Press 2010.
9. Kennedy A.S., Dezarin W.A., McNeillie P. et al.: Radioembolization for unresectable Neuroendocrine Hepatic Metastatic Using Resin 90Y Microspheres: Early Results in 148 Patients. Am. J. Clin. Oncol. 2008 Jun; 31(3): 271-9.
10. Moertel C.G., Kvols L.K., O’Connell M.U. et al.: Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasm. Cancer 1991; 68: 227-232.
11. Mitry E., Baudin E., Ducreux M. et al.: Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin. Br. J. Cancer 1999; 81: 1351-1355.
12. Hainsworth J.D., Spigel D.R., Litchy S. et al.: Phase II trial of paclitaxel, carboplatin, and etoposide in advanced poorly differentiated neuroendocrine carcinoma a Minnie Pearl Cancer Research Network Study. J. Clin. Oncol. 2006; 24: 3548-3554.
13. Bajetta E., Catena L., Procopio G. et al.: Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours? Cancer Chemother. Pharmacol. 2007; 59: 632-642.
14. Turner N.C., Strauss S.J., Sarker D. et al.: Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours. Br. J. Cancer 2010; 102: 1106-12.
15. Okita N.T., Kato K., Takahari D. et al.: Neuroendocrine tumors of the stomach: chemotherapy with cisplatin plus irinotecan is effective for gastric poorly-differentiated neuroendocrine carcinoma. Gastric Cancer 2011; 14: 161-5.
16. DiMeglio G., Massacesi C., Radice D. et al.: Carboplatin with etoposide in patients with extrapulmonary aggressive neuroendocrine carcinoma. J. Clin. Oncology 2010; 28: abstract e13072.
17. Broder L.E., Carter S.K.: Pancreatic islet cell carcinoma. I. Clinical features of 52 patients. Ann. Intern. Med. 1973; 79: 101-107.
18. Moertel C.G., Hanley J.A., Johnson L.A.: Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma. N. Engl. J. Med. 1980; 303: 1189-94.
19. Moertel C.G., Lefkopoulo M., Lipsitz S. et al.: Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N. Engl. J. Med 1992; 326: 519-23.
20. Öberg K.: Management of neuroendocrine tumours. Ann. Oncol. 2004; suppl. 4: 293-8.
21. O’Toole D., Hentic O., Corcos O., Ruszniewski P.: Chemotherapy for gastro-enteropancreatic endocrine tumours. Neuroendocrinology 2004; 80 (suppl. 1): 79-84.
22. Cheng P.N., Saltz L.B.: Failure to confirm major objective antitumor activity for streptozocin and doxorubicin in the treatment of patients with advanced islet cell carcinoma. Cancer 1999; 86: 944-8.
23. McCollum A.D., Kulke M.H., Ryan D.P. et al.: Lack of efficacy of streptozocin and doxorubicin in patients with advanced pancreatic neuroendocrine tumors. Am. J. Clin. Oncol. 2004; 27: 485-488.
24. Delaunoit T., Ducreux M., Boige V. et al.: The doxorubicin-streptozotocin combination for the treatment of advanced well-differentiated pancreatic endocrine carcinoma; a judicious option? Eur. J. Cancer 2004; 40: 515-20.
25. Kouvaraki M.A., Ajani J.A., Hoff P. et al.: Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J. Clin. Oncol. 2004; 22: 4762-71.
26. Fjallskog M.L., Janson E.T., Falkmer U.G. et al.: Treatment with combined streptozotocin and liposomal doxorubicin in metastatic endocrine pancreatic tumors. Neuroendocrinology 2008; 88: 55-58.
27. Corrie P., Caplin M., Reed N.: Treatment of advanced neuroendocrine tumors. Results of the UKINETS and NCRI randomized phase II NET01 trial. J. Clin. Oncol. 2012; 30 (suppl.): abstr. 4121.
28. Ramanathan R.K., Cnaan A., Hahn R.G. et al.: Phase II trial of dacarbazine (DTIC) in advanced pancreatic islet cell carcinoma: Study of the Eastern Cooperative Oncology Group E-6282. Ann. Oncol. 2001; 12: 1139-1143.
29. Kulke M., Stuart K., Enzinger P.C. et al.: Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J. Clin. Oncol. 2006; 24: 401-406.
30. Kulke M.H., Stuart K., Earle C.C. et al.: A phase II study of temozolomide and bevacizumab in patients with advanced neuroendocrine tumors. J. Clin. Oncol. 2006; 24(18S): 4044.
31. Strosberg J.R., Fine R.L., Choi J. et al.: First Line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer 2011; 117: 268-275.
32. Ekeblad S., Sundin A., Janson E.T. et al.: Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clin. Cancer Res. 2007; 13: 2986-2991.
33. Kulke M.H., Hornick J.L., Frauenhoffer C. et al.: O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors. Clin. Cancer Res. 2009; 15: 388-345.
34. Cassier P.A., Walter T., Eymard B. et al.: Gemcitabine and Oxaliplatin Combination Chemotherapy for Metastatic Well-differentiated Neuroendocrine Carcinomas. Cancer 2009; 115: 3392-9
35. Engstrom P.F., Lavin P.T., Moertel C.G. et al.: Streptozocin plus fluorouracil versus doxorubicin therapy for metastatic carcinoid tumor. J. Clin. Oncol. 1984; 2: 1255-1259.
36. Moertel C.G., Hanley J.A.: Combination chemotherapy trials in metastatic carcinoid tumor and the malignant carcinoid syndrome. Cancer Clin. Trials 1979; 2: 327-34.
37. Frame J., Kelsen D., Kemeny N. et al.: A phase II trial of streptozotocin and adriamycin in advanced APUD tumors. Am. J. Clin. Oncol. 1988; 11: 490-5.
38. Sun W., Lipsitz S., Catalano P. et al.: Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281. J. Clin. Oncol. 2005; 23: 4897-4904.
39. Bukowski R.M., Tangen C.M., Peterson R.F. et al.: Phase II trial of dimethyltriazenoimidazole carboxamide in patients with metastatic carcinoid. A Southwest Oncology Group study. Cancer 1994; 73: 1505-1508.
2. Gaur P., Sceusi E.L., Samuel S. et al.: Identification of cancer stem cells in human gastrointestinal carcinoid and neuroendocrine tumors. Gastroenterology 2011; 141: 1728-1737.
3. Modlin I.M., Oberg K., Chung D.C. et al.: Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol. 2008; 9: 61-72.
4. Kos-Kudła B.: Polskie zalecenia diagnostyczno-lecznicze w guzach neuroendokrynnych układu pokarmowego (GEP NET). Nowotwory J. of Oncology 2006; 56: 584-589.
5. Oberg K.: Pancreatic endocrine tumors. Semin. Oncol. 2010; 37: 594-618.
6. Kulke M.H., Siu L.L., Tepper J.E. et al.: Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting. J. Clin. Oncol. 2011; 29: 934-943.
7. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology, Neuroendocrine Tumors Version 1.2011. Online: http://www.nccn.org.
8. Bosman F., Carneiro F., Hruban R. et al.: WHO classification of tumors of digestive system. Lyon, IARC Press 2010.
9. Kennedy A.S., Dezarin W.A., McNeillie P. et al.: Radioembolization for unresectable Neuroendocrine Hepatic Metastatic Using Resin 90Y Microspheres: Early Results in 148 Patients. Am. J. Clin. Oncol. 2008 Jun; 31(3): 271-9.
10. Moertel C.G., Kvols L.K., O’Connell M.U. et al.: Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasm. Cancer 1991; 68: 227-232.
11. Mitry E., Baudin E., Ducreux M. et al.: Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin. Br. J. Cancer 1999; 81: 1351-1355.
12. Hainsworth J.D., Spigel D.R., Litchy S. et al.: Phase II trial of paclitaxel, carboplatin, and etoposide in advanced poorly differentiated neuroendocrine carcinoma a Minnie Pearl Cancer Research Network Study. J. Clin. Oncol. 2006; 24: 3548-3554.
13. Bajetta E., Catena L., Procopio G. et al.: Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours? Cancer Chemother. Pharmacol. 2007; 59: 632-642.
14. Turner N.C., Strauss S.J., Sarker D. et al.: Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours. Br. J. Cancer 2010; 102: 1106-12.
15. Okita N.T., Kato K., Takahari D. et al.: Neuroendocrine tumors of the stomach: chemotherapy with cisplatin plus irinotecan is effective for gastric poorly-differentiated neuroendocrine carcinoma. Gastric Cancer 2011; 14: 161-5.
16. DiMeglio G., Massacesi C., Radice D. et al.: Carboplatin with etoposide in patients with extrapulmonary aggressive neuroendocrine carcinoma. J. Clin. Oncology 2010; 28: abstract e13072.
17. Broder L.E., Carter S.K.: Pancreatic islet cell carcinoma. I. Clinical features of 52 patients. Ann. Intern. Med. 1973; 79: 101-107.
18. Moertel C.G., Hanley J.A., Johnson L.A.: Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma. N. Engl. J. Med. 1980; 303: 1189-94.
19. Moertel C.G., Lefkopoulo M., Lipsitz S. et al.: Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N. Engl. J. Med 1992; 326: 519-23.
20. Öberg K.: Management of neuroendocrine tumours. Ann. Oncol. 2004; suppl. 4: 293-8.
21. O’Toole D., Hentic O., Corcos O., Ruszniewski P.: Chemotherapy for gastro-enteropancreatic endocrine tumours. Neuroendocrinology 2004; 80 (suppl. 1): 79-84.
22. Cheng P.N., Saltz L.B.: Failure to confirm major objective antitumor activity for streptozocin and doxorubicin in the treatment of patients with advanced islet cell carcinoma. Cancer 1999; 86: 944-8.
23. McCollum A.D., Kulke M.H., Ryan D.P. et al.: Lack of efficacy of streptozocin and doxorubicin in patients with advanced pancreatic neuroendocrine tumors. Am. J. Clin. Oncol. 2004; 27: 485-488.
24. Delaunoit T., Ducreux M., Boige V. et al.: The doxorubicin-streptozotocin combination for the treatment of advanced well-differentiated pancreatic endocrine carcinoma; a judicious option? Eur. J. Cancer 2004; 40: 515-20.
25. Kouvaraki M.A., Ajani J.A., Hoff P. et al.: Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J. Clin. Oncol. 2004; 22: 4762-71.
26. Fjallskog M.L., Janson E.T., Falkmer U.G. et al.: Treatment with combined streptozotocin and liposomal doxorubicin in metastatic endocrine pancreatic tumors. Neuroendocrinology 2008; 88: 55-58.
27. Corrie P., Caplin M., Reed N.: Treatment of advanced neuroendocrine tumors. Results of the UKINETS and NCRI randomized phase II NET01 trial. J. Clin. Oncol. 2012; 30 (suppl.): abstr. 4121.
28. Ramanathan R.K., Cnaan A., Hahn R.G. et al.: Phase II trial of dacarbazine (DTIC) in advanced pancreatic islet cell carcinoma: Study of the Eastern Cooperative Oncology Group E-6282. Ann. Oncol. 2001; 12: 1139-1143.
29. Kulke M., Stuart K., Enzinger P.C. et al.: Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J. Clin. Oncol. 2006; 24: 401-406.
30. Kulke M.H., Stuart K., Earle C.C. et al.: A phase II study of temozolomide and bevacizumab in patients with advanced neuroendocrine tumors. J. Clin. Oncol. 2006; 24(18S): 4044.
31. Strosberg J.R., Fine R.L., Choi J. et al.: First Line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer 2011; 117: 268-275.
32. Ekeblad S., Sundin A., Janson E.T. et al.: Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clin. Cancer Res. 2007; 13: 2986-2991.
33. Kulke M.H., Hornick J.L., Frauenhoffer C. et al.: O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors. Clin. Cancer Res. 2009; 15: 388-345.
34. Cassier P.A., Walter T., Eymard B. et al.: Gemcitabine and Oxaliplatin Combination Chemotherapy for Metastatic Well-differentiated Neuroendocrine Carcinomas. Cancer 2009; 115: 3392-9
35. Engstrom P.F., Lavin P.T., Moertel C.G. et al.: Streptozocin plus fluorouracil versus doxorubicin therapy for metastatic carcinoid tumor. J. Clin. Oncol. 1984; 2: 1255-1259.
36. Moertel C.G., Hanley J.A.: Combination chemotherapy trials in metastatic carcinoid tumor and the malignant carcinoid syndrome. Cancer Clin. Trials 1979; 2: 327-34.
37. Frame J., Kelsen D., Kemeny N. et al.: A phase II trial of streptozotocin and adriamycin in advanced APUD tumors. Am. J. Clin. Oncol. 1988; 11: 490-5.
38. Sun W., Lipsitz S., Catalano P. et al.: Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281. J. Clin. Oncol. 2005; 23: 4897-4904.
39. Bukowski R.M., Tangen C.M., Peterson R.F. et al.: Phase II trial of dimethyltriazenoimidazole carboxamide in patients with metastatic carcinoid. A Southwest Oncology Group study. Cancer 1994; 73: 1505-1508.